# Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00723359** · PHASE1 · COMPLETED · sponsor: **Biotest Pharmaceuticals Corporation** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** BT062

## Key facts

- **NCT ID:** NCT00723359
- **Lead sponsor:** Biotest Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00723359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00723359, "Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00723359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*